Michael Roukes, Ph.D. - Contact Card
Keynote Speech: “Can we reverse-engineer the brain?”
Professor Roukes completed undergraduate majors in both physics and chemistry at the University of California Santa Cruz, and thereafter earned a Ph.D. in physics at Cornell University, focusing upon electron transport in microstructures at ultralow temperatures. Subsequently, he joined Bell Communications Research as a Member of Technical Staff/Principal Investigator in the (then-new) Quantum Structures Research Group, where he carried out some of the earliest explorations of the physics of nanoelectronic devices. In 1992 he joined the tenured faculty at the California Institute of Technology, where he built nanofabrication facilities and has established a large nanoscience research group, now heavily involved in cross-disciplinary collaborations. Roukes’ scientific interests range from fundamental science to applied biotechnology, with a unifying theme centered upon development, application, and very-large-scale-integration of complex nanostructures. He has published and written extensively on nanoscience and nanotechnology, has lectured at most major research centers world-wide, and is active on many national and international committees that promote this field. Professor Roukes was founding Director of Caltech’s Kavli Nanoscience Institute in 2003-2006, co-Director in 2008-2013, and has recently stepped down to focus full-time on collaborative research in neuroscience, nanoscience, and biotechnology.
Keynote Speech: “Advanced development for long-term, fully implantable glucose sensors”
Dr. DeHennis has achieved degrees in both Physics and Electrical Engineering with focuses on Solid-State Devices as well as Micro-Electro Mechanical Systems (MEMS). His Ph.D. from the University of Michigan in 2004 focused on wireless sensors that spanned applications in biomedical as well as environmental monitoring systems. He has spent his professional career working to make long-term implantable analyte sensing a reality in achieving the launch of the Eversense Continuous Glucose Monitoring (CGM) system. His team’s current work focuses on scale-up and support of the Eversense system, continued R&D in system architecture and algorithm development, as well as clinical evaluation and regulatory strategy for next-generation CGM systems. Spanning his academic and professional career, he has over two dozen published papers and patents in the field of sensors, which span the technological building blocks and long-term in vivo performance and characterization of the Eversense CGM system.
Keynote Speech: "Chemistry-free microfluidic technologies to sort cells for health and disease"
Dr. Utkan Demirci, UofM’99, Stanford’01’05, is a Professor of Radiology (with tenure) and of Electrical Engineering (by courtesy) at the Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, where he leads a productive group of ~20 researchers. Dr. Demirci’s lab is focused on creating micro- and nano-scale technologies that manipulate cells to enable solutions for real world problems in medicine. His group has pioneering contributions in multiple fields including infectious diseases, fertility, cancer diagnostics, cell encapsulation, cryobiology, and biofabrication. His research interests involve the application of microfluidics, nanoscale technologies and acoustics in medicine as it pertains to portable, inexpensive, disposable viral load technology platforms for HIV in resource-constrained settings for global health problems, as well as 3-D bioprinting and tissue models, including 3-D cancer and neural cultures. He has earned many awards including IEEE EMBS Early Career, NSF Career, MIT TR-35, and fellow-elect AIMBE. He holds over 20 patents, provisional, and disclosures and his patents have been translated into products through multiple start-up companies including DxNOW, Koek Biotechnology and LEVITAS. Some of the technologies developed in his lab are now clinically available across the globe, with over 10,000 live births in the US, Europe and Turkey being attributed to the sperm selection technology that came out of Dr. Demirci's lab.